Biogen, Isis unite for the 4th time to develop neurological drugs

09/10/2013 | Reuters · Genetic Engineering & Biotechnology News

Biogen Idec signed a deal with Isis Pharmaceuticals to develop new treatments for neurological diseases using the latter's antisense technology. The current deal, which entitles Isis to $100 million upfront, is the fourth collaboration between the firms in the past two years. Isis will get milestone and licensing fees plus sales royalties on products arising from the collaboration.

View Full Article in:

Reuters · Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY